RxDoctor Payments DataLook up a doctor →

Frederick Herman, MD

Allergy & Immunology · Henderson, NVNPI 1811149610

Payments from drug & device makers

$35,052in general payments, 2019–2025

Across 884 payments — averaging $39.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$11K
  • Optinose US, Inc.$10K
  • AstraZeneca$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • GSK$1K
  • CSL Behring$1K
  • plus $7K from 36 others

What the payments were for

  • Consulting fees$9683%
  • Speaking & faculty fees$19,10555%
  • Travel & lodging$1500%
  • Food & beverage$14,20241%
  • Education$6282%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$389,816
Medicare patients
418
Services billed
22,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab126$469,054
NucalaMepolizumab41$276,052
XolairOmalizumab96$189,392
HizentraImmun Glob G(Igg)/Pro/Iga 0-5021$95,997
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$90,900
Fasenra PenBenralizumab12$79,071
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$38,551
XhanceFluticasone Propionate16$9,682
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,120
Zafirlukast80$6,851
Epinephrine31$5,705
Cromolyn Sodium15$4,676
Ipratropium Bromide145$4,073
Minocycline Hcl137$3,396
Cyproheptadine Hcl119$3,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta$1,494$283,17252 claims
CSL BehringHizentra, Privigen$1,437$134,54832 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$1,039$90,90016 claims
Optinose US, Inc.Xhance$9,581$9,68216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →